# A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending and Multiple Doses of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Healthy Japanese Participants

> **NCT04302064** · PHASE1 · COMPLETED · sponsor: **Ionis Pharmaceuticals, Inc.** · enrollment: 24 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** Eplontersen
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04302064
- **Lead sponsor:** Ionis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-23
- **Primary completion:** 2020-09-10
- **Final completion:** 2020-09-10
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2022-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04302064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04302064, "A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending and Multiple Doses of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Healthy Japanese Participants". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04302064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*